Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics–Based Analysis of Adult Patients With Invasive Fungal Infections

Population Pharmacokinetics of Voriconazole in Adults

(2011) William W. Hope   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Observational Study of the Clinical Efficacy of Voriconazole and Its Relationship to Plasma Concentrations in Patients

(2011) Peter F. Troke et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Population Pharmacokinetic Evaluation with External Validation and Bayesian Estimator of Voriconazole in Liver Transplant Recipients

(2011) Kelong Han et al.   CLINICAL PHARMACOKINETICS

Comparison of In Vitro Susceptibility Characteristics ofCandidaSpecies from Cases of Invasive Candidiasis in Solid Organ and Stem Cell Transplant Recipients: Transplant-Associated Infections Surveillance Network (TRANSNET), 2001 to 2006

(2011) Shawn R. Lockhart et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Evaluation of Hepatotoxicity with Off-Label Oral-Treatment Doses of Voriconazole for Invasive Fungal Infections

(2010) Elizabeth Gorski et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Use of Epidemiological Cutoff Values To Examine 9-Year Trends in Susceptibility of Aspergillus Species to the Triazoles

(2010) M. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

National Surveillance of Fungemia in Denmark (2004 to 2009)

(2010) M. C. Arendrup et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation

(2009) S. M. Trifilio et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Voriconazole Pharmacokinetics and Pharmacodynamics in Children

(2009) Michael Neely et al.   CLINICAL INFECTIOUS DISEASES

Activities of Antifungal Agents against Yeasts and Filamentous Fungi: Assessment according to the Methodology of the European Committee on Antimicrobial Susceptibility Testing

(2008) C. Lass-Florl et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

International Interlaboratory Proficiency Testing Program for Measurement of Azole Antifungal Plasma Concentrations

(2008) R. J. M. Bruggemann et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Antifungal Therapeutic Drug Monitoring: Established and Emerging Indications

(2008) D. Andes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Voriconazole plasma monitoring

(2008) A C Pasqualotto et al.   ARCHIVES OF DISEASE IN CHILDHOOD

Hallucinations during Voriconazole Therapy

(2008) Dimitrios I. Zonios et al.   CLINICAL INFECTIOUS DISEASES

Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America

(2008) Thomas J. Walsh et al.   CLINICAL INFECTIOUS DISEASES

Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria

(2008) Brahm H. Segal et al.   CLINICAL INFECTIOUS DISEASES

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES

Therapeutic drug monitoring for triazoles

(2008) William W Hope et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Pharmacokinetic–pharmacodynamic analysis of voriconazole in Japanese patients with hematological malignancies

(2008) K. Nomura et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers

(2008) Guo Wang et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes

(2007) A. Pascual et al.   CLINICAL INFECTIOUS DISEASES